arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2003-9-5-164-166arthyper-889Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESРоль блокаторов ангиотензиновых рецепторов типа 1 в коррекции артериальной гипертензии у женщин фертильного возрастаRole of type 1 angiotensin-receptor blockers in the correction of arterial hypertension in fertile-age womenТурдиалиеваС. А.TurdialiyevaS. A.noemail@neicon.ruЛинчакР. М.LinchakR. M.noemail@neicon.ruСвистовА. С.SvistovA. S.noemail@neicon.ruБойцовС. А.BoitsovS. A.noemail@neicon.ruКарпенкоМ. А.KarpenkoM. A.noemail@neicon.ruВоенно-медицинская академия им. С.М. КироваRussian FederationФГБУ «ГНИЦ ПМ» Минздравсоцразвития РФ; ФГБУ «Государственный научно-исследовательский центр профилактической медицины» МЗиСРRussian FederationФГБУ «Федеральный Центр сердца, крови и эдокринологии им. В.А. Алмазова» Минздрава РоссииRussian Federation20032810200395164166Copyright © Турдиалиева С.А., Линчак Р.М., Свистов А.С., Бойцов С.А., Карпенко М.А., 20032003Турдиалиева С.А., Линчак Р.М., Свистов А.С., Бойцов С.А., Карпенко М.А.Turdialiyeva S.A., Linchak R.M., Svistov A.S., Boitsov S.A., Karpenko M.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/889

Проведена оценка гипотензивного эффекта диована при медикаментозной коррекции артериальной гипертензии (АГ) у женщин фертильного возраста. Изучены особенности гипотензивного действия диована в зависимости от полиморфизма генов ангиотензинпревращающиего фермента (АПФ) и антагониста рецепторов типа 1 к ангиотензину II (АТР1). Установлено, что применение диована (80 мг в сутки) для коррекции АГ у женщин фертильного возраста обеспечивает нормализацию суточного профиля артериального давления, улучшение липидного спектра и кардиопротекцию. Определено наличие ассоциации между эффективностью диована и структурным состоянием генов АПФ и АТР1. Максимальную эффективность препарата можно ожидать у больных с генотипом DD (ген АПФ) и генотипом АС (ген АТР1).

The antihypertensive effect of diovan in the medical correction of arterial hypertension (AH) was tested in fertile-age women. The specific features of the agent were studied in relation to the gene polymorphism of angiotensin-converting enzyme (ACE) and antagonists of type 1 receptors to angiolensin-ll receptor blockers (ATR1). The use of diovan, 80 mg daily, to correct AH in fertile-age females was found to promote the normalization of the daily blood pressure profile, the improvement of the lipid spectrum, and cardioprotection. There was an association of the efficacy of diovan and the structural status of ACE and ATR1 genes. The maximum efficacy of the drug may be expected in patients with DD genotype (ACE gene) and AC genotype (ATP1 gene).

эссенциальная гипертензияфертильный возрастдиовангенетикаполиморфизм геновessential hypertensionfertile agediovangeneticsgene polymorphismReferencesCifkova R., Peleska J., Hradec J., Rosolova H., Pinterova E., Zeman K., Oddou Strock P., Thirlwell J., Botteri F. Valsartan and atenolol in patients with severe essential hypertension. J Hum Hypertens. 1998 Aug;12 (8): 563-7.Cifkova R., Peleska J., Hradec J., Rosolova H., Pinterova E., Zeman K., Oddou Strock P., Thirlwell J., Botteri F. Valsartan and atenolol in patients with severe essential hypertension. J Hum Hypertens. 1998 Aug;12 (8): 563-7.Holwerda N.J., Fogari R., Angeli P., Porcellati C., Herenq C., Oddou-Stock P., Heath R., Bodin F. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens. 1996 Sep;14 (9): 1147-51.Holwerda N.J., Fogari R., Angeli P., Porcellati C., Herenq C., Oddou-Stock P., Heath R., Bodin F. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens. 1996 Sep;14 (9): 1147-51.Hegner G., Faust G., Freitag F., Meilenbrock S., Sullivan J., Bodin F. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide. Eur J Clin Pharmacol. 1997; 52 (3): 173-7.Hegner G., Faust G., Freitag F., Meilenbrock S., Sullivan J., Bodin F. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide. Eur J Clin Pharmacol. 1997; 52 (3): 173-7.Viberti G., Wheeldon N.M., MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002 Aug 6; 106 (6): 672-8.Viberti G., Wheeldon N.M., MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002 Aug 6; 106 (6): 672-8.Pool J., Oparil S., Hedner T. et al. Valsartan is an effective antihypertensive in both women and men: an integrated analysis. Am J Hypertens 2000; 13: 278.Pool J., Oparil S., Hedner T. et al. Valsartan is an effective antihypertensive in both women and men: an integrated analysis. Am J Hypertens 2000; 13: 278.Bremner A.D., Mehring G.H., Mielenbrock S. Long-term systemic tolerability of valsartan compared with lisinopril in elderly hypertensive patients. Adv Ther 1997: 14: 245-53.Bremner A.D., Mehring G.H., Mielenbrock S. Long-term systemic tolerability of valsartan compared with lisinopril in elderly hypertensive patients. Adv Ther 1997: 14: 245-53.Patet JKV, Leaback R. on behalf of the POSATIV investigators. Patients of Soutbern Asian descent treated with valsartan (POSATIV) study. Br J Cardiot 2002; 9: 351-4.Patet JKV, Leaback R. on behalf of the POSATIV investigators. Patients of Soutbern Asian descent treated with valsartan (POSATIV) study. Br J Cardiot 2002; 9: 351-4.Schmieder R.E., Martus P., Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA. 1996 May 15; 275 (19): 1507-13.Schmieder R.E., Martus P., Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA. 1996 May 15; 275 (19): 1507-13.Natbantgil S., Yilmaz H., Gurun C et al. Effects of valsartan and enalapril on regression of left ventricular hypertrophy in patients with mild to moderate hypertension: a randomized, double-blind study. GurrTher Res Clin E 200; 61: 331-8.Natbantgil S., Yilmaz H., Gurun C et al. Effects of valsartan and enalapril on regression of left ventricular hypertrophy in patients with mild to moderate hypertension: a randomized, double-blind study. GurrTher Res Clin E 200; 61: 331-8.Parving H.H., Legnert H., Brocher-Mortensen J., Gomis R., Andersen S., Arner P., Irbesartan in Patients with Type 2 Diabetes and Microalbuminuris Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001 Sep 20; 345 (12): 870-8.Parving H.H., Legnert H., Brocher-Mortensen J., Gomis R., Andersen S., Arner P., Irbesartan in Patients with Type 2 Diabetes and Microalbuminuris Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001 Sep 20; 345 (12): 870-8.Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., Ritz E., Atkins R.C., Rohde R., Raz I., Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20; 345 (12): 851-60.Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., Ritz E., Atkins R.C., Rohde R., Raz I., Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20; 345 (12): 851-60.Fogari R., Preti P., Derosa G., Marasi G., Zoppi A., Rinaldi A., Mugellini A. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol. 2002 Jun; 58 (3): 177-80. Epub 2002 May 1.Fogari R., Preti P., Derosa G., Marasi G., Zoppi A., Rinaldi A., Mugellini A. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol. 2002 Jun; 58 (3): 177-80. Epub 2002 May 1.Диденко В.А., Симонова Д.В. Влияние блокаторов рецепторов ангиотензина II лозартана на метаболические показатели и морфофункциональное состояние миокарда в процессе терапии больных гипертонической болезнью. Клин. медицина 1998; 9: 33-7.Диденко В.А., Симонова Д.В. Влияние блокаторов рецепторов ангиотензина II лозартана на метаболические показатели и морфофункциональное состояние миокарда в процессе терапии больных гипертонической болезнью. Клин. медицина 1998; 9: 33-7.Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe-Pedersen O., Lindholm L.H., Nieminen M.S., Omvik P., Oparil S., Wedel H., LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002 Mar 23; 359 (9311): 995-1003.Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe-Pedersen O., Lindholm L.H., Nieminen M.S., Omvik P., Oparil S., Wedel H., LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002 Mar 23; 359 (9311): 995-1003.Fogari R., Zoppi A., Mugellini A. et al. Comparative effect of losartan and valsartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring. Curr. Ther Res Clin E 1999: 60: 195-206.Fogari R., Zoppi A., Mugellini A. et al. Comparative effect of losartan and valsartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring. Curr. Ther Res Clin E 1999: 60: 195-206.Cannella G., Paoletti E., Barocci S., Massarino F., Delfino R., Ravera G., Di Maio G., Nocera A., Patrone P., Rolla D. Angiotensin-converting enzyme gene polymorphism and reversibility of uremic left ventricular hypertrophy following long-term antihypertensive therapy. Kidney Int. 1998 Aug; 54 (2): 618-26.Cannella G., Paoletti E., Barocci S., Massarino F., Delfino R., Ravera G., Di Maio G., Nocera A., Patrone P., Rolla D. Angiotensin-converting enzyme gene polymorphism and reversibility of uremic left ventricular hypertrophy following long-term antihypertensive therapy. Kidney Int. 1998 Aug; 54 (2): 618-26.Kohno M., Yokokawa K., Minami M., Kano H., Yasunari K., Hanehira T., Yoshikawa J. Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors. Am J Med. 1999 May; 106 (5): 544-9.Kohno M., Yokokawa K., Minami M., Kano H., Yasunari K., Hanehira T., Yoshikawa J. Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors. Am J Med. 1999 May; 106 (5): 544-9.Cheung R., Lewanczuk R.Z., Rodger N.W., Huff M.W., Oddou-Stock P., Botteri F., Pecher E., Muirhead N. The effect of valsartan and captopril on lipid parameters in patients with type II diabetes mellitus and nephropathy. Int J Clin Pract. 1999 Dec; 53 (8): 584-92.Cheung R., Lewanczuk R.Z., Rodger N.W., Huff M.W., Oddou-Stock P., Botteri F., Pecher E., Muirhead N. The effect of valsartan and captopril on lipid parameters in patients with type II diabetes mellitus and nephropathy. Int J Clin Pract. 1999 Dec; 53 (8): 584-92.Cianflone K.M., Yasruel Z., Rodrigues M.A., Vas D., Sniderman A.D. Regulation of apoB secretion from HepG2 cells: evidence for a critical role for cholesteryl ester synthesis in the response to a fatty acid challenge. J Lipid Res. 1990 Nov; 31 (11): 2045-55.Cianflone K.M., Yasruel Z., Rodrigues M.A., Vas D., Sniderman A.D. Regulation of apoB secretion from HepG2 cells: evidence for a critical role for cholesteryl ester synthesis in the response to a fatty acid challenge. J Lipid Res. 1990 Nov; 31 (11): 2045-55.Schafer F.J., Levy R.I. Pathogenesis and management of lipoprotein disorders. N Engi J Med 1985; 312: 1300-10.Schafer F.J., Levy R.I. Pathogenesis and management of lipoprotein disorders. N Engi J Med 1985; 312: 1300-10.Thompson G.R., Naoumova R.P., Watts G.R. Role of cholesterol in regulating apolipoprotein B secretion by the liver. J Lipid Res. 1996 Mar; 37 (3): 439-47.Thompson G.R., Naoumova R.P., Watts G.R. Role of cholesterol in regulating apolipoprotein B secretion by the liver. J Lipid Res. 1996 Mar; 37 (3): 439-47.Litwin S.E., Grossman W. Diastolic dysfunction as a cause of heart failure. J Am Coll Cardiol. 1993 Oct; 22 (4 Suppl A): 49A-55A.Litwin S.E., Grossman W. Diastolic dysfunction as a cause of heart failure. J Am Coll Cardiol. 1993 Oct; 22 (4 Suppl A): 49A-55A.

The authors declare that there are no conflicts of interest present.